Table III.
Results of cell viability assays following nanoparticle or free drug treatment for 48 h.
| IC50 (µg/ml) | ||||
|---|---|---|---|---|
| OVCAR-3 | PA-1 | |||
| Treatment | CD133+ | CD133− | CD133+ | CD133− |
| Salinomycin | 6.53±2.71 | 13.82±6.56 | 9.12±3.45 | 11.54±6.94 |
| SAL-NP | 12.34±5.73 | 18.12±5.93 | 14.79±5.67 | 18.05±6.04 |
| CD133-SAL-NP | 1.98±1.59 | 19.35±6.44 | 4.42±2.11 | 19.58±3.43 |
| CD133-NP | >250.0 | >250.0 | >250.0 | >250.0 |
Data are expressed as the mean ± standard deviation (n=3). IC50, half maximal inhibitory concentration; CD, cluster of differentiation; SAL-NP, salinomycin-loaded poly(lactic-co-glycolic acid) nanoparticles; CD133-SAL-NP, salinomycin-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 antibodies; CD133-NP, poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 antibodies.